300529.SZ
健帆生物
SZSE · Healthcare · C 制造业 · CN
CNY 15.56
−1.27%Income statement
| Metric | TTM | 2025 | 2024 | 2023 | 2022 |
|---|---|---|---|---|---|
| Revenue | |||||
| Total Revenue | 2.0B | 2.0B | 2.7B | 1.9B | 2.5B |
| Cost of Revenue | 450.5M | 428.5M | 514.6M | 389.5M | 440.1M |
| Gross Profit | 1.6B | 1.6B | 2.2B | 1.5B | 2.1B |
| Operating Expenses | |||||
| R&D Expense | 191.2M | 198.4M | 240.1M | 245.4M | 253.9M |
| SG&A Expense | — | — | — | — | — |
| General & Admin Expense | 124.5M | 131.7M | 189.2M | 177.4M | 138.1M |
| Selling & Marketing Expense | 471.6M | 501.5M | 692.0M | 610.5M | 700.6M |
| Other Expenses | — | — | — | — | — |
| Total Operating Expenses | 864.8M | 910.0M | 1.2B | 1.0B | 1.1B |
| Cost and Expenses | 1.3B | 1.3B | 1.7B | 1.4B | 1.6B |
| Operating Income (EBIT) | 715.5M | 690.8M | 1.0B | 543.8M | 1.0B |
| Non-Operating | |||||
| Interest Income | — | — | — | — | — |
| Interest Expense | — | — | — | — | — |
| Net Interest Income | — | — | — | — | — |
| Other Non-Op Income/Expense | — | — | — | — | — |
| Non-Operating Income (excl Interest) | — | — | — | — | — |
| EBT (Pre-Tax Income) | 695.0M | 660.1M | 1.0B | 521.0M | 1.0B |
| Income Tax Expense | 130.9M | 128.5M | 192.8M | 95.3M | 135.9M |
| Bottom Line | |||||
| Net Income | 564.6M | 532.8M | 820.2M | 436.5M | 889.6M |
| Earnings from Cont. Ops | 564.1M | 531.7M | 814.2M | 425.7M | 880.9M |
| Earnings from Discont. Ops | — | — | — | — | — |
| Bottom Line Net Income | 564.6M | 532.8M | 820.2M | 436.5M | 889.6M |
| Per Share | |||||
| Basic EPS | CN¥0.73 | CN¥0.69 | CN¥1.05 | CN¥0.55 | CN¥1.12 |
| Diluted EPS | CN¥0.73 | CN¥0.69 | CN¥1.07 | CN¥0.57 | CN¥1.13 |
| Revenue Per Share | CN¥2.57 | CN¥2.61 | CN¥3.43 | CN¥2.42 | CN¥3.14 |
| Shares | |||||
| Basic Shares Outstanding | 787.5M | 772.2M | 781.1M | 793.6M | 794.3M |
| Diluted Shares Outstanding | 787.5M | 772.2M | 781.1M | 793.6M | 794.3M |
| Profitability Metrics | |||||
| EBITDA | — | 824.5M | 1.2B | 652.5M | 1.1B |
| D&A | — | 133.7M | 140.9M | 108.6M | 77.7M |
| EBIT | — | — | — | — | — |
As reported, in the filing currency · TTM sums the four latest quarters; MRQ is the latest quarter · Negatives in parentheses; a dash is a line the filing does not carry · Data as of Mar 1, 2026